Beta

Beyondspring inc.BYSI.US Overview

US StockHealthcare
(No presentation for BYSI)
OverviewAI AnalysisFinancialsFinancial ForecastStock SentimentalInstitutionsTradingView Chart

Ticker

Value

empty

There is no following symbol in this watchlist.

BYSI AI Insights

BYSI Overall Performance

BYSI AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

BYSI Recent Performance

-3.21%

Beyondspring inc.

-1.10%

Avg of Sector

-0.49%

S&P500

BYSI PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

Check BYSI's Trend

BYSI Key Information

BYSI Valuation Metrics

BYSI Profile

BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody for the treatment of SCLC; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform. The company was founded in 2010 and is headquartered in New York, New York.

Price of BYSI

BYSI FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

BYSI Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.02
PE Ratio (TTM)
-
Forward PE
10.54
PS Ratio (TTM)
45.99
PB Ratio
5.38
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
100.00%
Net Margin
119.00%
Revenue Growth (YoY)
100.00%
Profit Growth (YoY)
100.00%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.02
PE Ratio (TTM)
-
Forward PE
10.54
PS Ratio (TTM)
45.99
PB Ratio
5.38
Price-to-FCF
-
Gross Margin
100.00%
Net Margin
119.00%
Revenue Growth (YoY)
100.00%
Profit Growth (YoY)
100.00%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%

  • When is BYSI's latest earnings report released?

    The most recent financial report for Beyondspring inc. (BYSI) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating BYSI's short-term business performance and financial health. For the latest updates on BYSI's earnings releases, visit this page regularly.

  • How much cash does BYSI have?

    At the end of the period, Beyondspring inc. (BYSI) held Total Cash and Cash Equivalents of 7.79M, accounting for 0.3 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is BYSI's EPS continuing to grow?

    According to the past four quarterly reports, Beyondspring inc. (BYSI)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.05. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What are the PEG ratio and PE ratio of BYSI?

    The latest valuation data shows Beyondspring inc. (BYSI) has a Price-To-Earnings (PE) ratio of -68.67 and a Price/Earnings-To-Growth (PEG) ratio of -0.06. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.